TB-500
Dosage Protocol
TB-500 is a synthetic fragment of Thymosin Beta-4 (TB4), a naturally occurring 43-amino-acid protein found in nearly all human and animal cells. It is studied for systemic wound healing, anti-inflammatory activity, and cell migration — with a unique ability to act at sites distant from the injection point.
What is TB-500?
Thymosin Beta-4 is one of the most abundant intracellular peptides in the body. TB-500, the synthetic fragment corresponding to the actin-binding domain (Ac-SDKP), retains many of TB4's key bioactivities. It promotes cell migration, proliferation, and differentiation — mechanisms central to tissue repair across muscle, tendon, skin, and cardiac tissue.
Unlike BPC-157, which tends to work locally near the injection site, TB-500 has demonstrated systemic activity in animal models. This means it may act on tissues throughout the body regardless of injection location. Researchers often combine it with BPC-157 (Wolverine Stack) for complementary local and systemic repair.
Dosing Schedule
Parameters documented in published preclinical and clinical research.
| Phase | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Loading phase weeks 1–6 | 10–20 mg/week | Split into 2 injections | 6 weeks | Higher dose phase documented in published loading protocols. |
| Maintenance phase | 5–10 mg/week | 1–2 injections | Ongoing as needed | Reduced dose phase documented in published maintenance protocols. |
| High-dose research phase | 20 mg/week | Split into 2 injections | 4–8 weeks | Used in studies examining acute injury models. |
| Off cycle | — | — | 4–8 weeks | Rest period between extended cycles. |